Nothing Special   »   [go: up one dir, main page]

MX2015001424A - Compuestos pirazolona sustituidos y metodos de uso. - Google Patents

Compuestos pirazolona sustituidos y metodos de uso.

Info

Publication number
MX2015001424A
MX2015001424A MX2015001424A MX2015001424A MX2015001424A MX 2015001424 A MX2015001424 A MX 2015001424A MX 2015001424 A MX2015001424 A MX 2015001424A MX 2015001424 A MX2015001424 A MX 2015001424A MX 2015001424 A MX2015001424 A MX 2015001424A
Authority
MX
Mexico
Prior art keywords
methods
compounds
pyrazolone compounds
substituted pyrazolone
compositions
Prior art date
Application number
MX2015001424A
Other languages
English (en)
Inventor
Ning Xi
Yanjun Wu
Min Liao
Yanming Feng
Original Assignee
Calitor Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calitor Sciences Llc filed Critical Calitor Sciences Llc
Publication of MX2015001424A publication Critical patent/MX2015001424A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee novedosos compuestos pirazolona sustituidos, sales farmacéuticamente aceptables y formulaciones de los mismos útiles en modular la actividad de la proteína tirosina cinasa, y en modular actividades celulares tales como proliferación, diferenciación, apoptosis, migración e invasión. La invención también provee composiciones farmacéuticas aceptables que comprenden tales compuestos y métodos de usar las composiciones en el tratamiento de desórdenes hiperproliferativos en mamíferos, especialmente seres humanos..
MX2015001424A 2012-07-28 2013-07-19 Compuestos pirazolona sustituidos y metodos de uso. MX2015001424A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261676944P 2012-07-28 2012-07-28
US201261679416P 2012-08-03 2012-08-03
PCT/US2013/051174 WO2014022116A2 (en) 2012-07-28 2013-07-19 Substituted pyrazolone compounds and methods of use

Publications (1)

Publication Number Publication Date
MX2015001424A true MX2015001424A (es) 2016-03-09

Family

ID=50028432

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015001424A MX2015001424A (es) 2012-07-28 2013-07-19 Compuestos pirazolona sustituidos y metodos de uso.

Country Status (11)

Country Link
US (1) US8969388B1 (es)
EP (2) EP2879676B1 (es)
JP (2) JP6342393B2 (es)
AU (1) AU2013296897B2 (es)
BR (1) BR112015001528B1 (es)
CA (1) CA2876246C (es)
ES (1) ES2634414T3 (es)
HK (1) HK1208341A1 (es)
MX (1) MX2015001424A (es)
RU (1) RU2650895C2 (es)
WO (2) WO2014022117A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969388B1 (en) * 2012-07-28 2015-03-03 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
WO2015164161A1 (en) * 2014-04-22 2015-10-29 Calitor Sciences, Llc Bicylcic pyrazolone compounds and methods of use
WO2016061231A1 (en) * 2014-10-14 2016-04-21 Deciphera Pharmaceuticals, Llc Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
CN106467541B (zh) * 2015-08-18 2019-04-05 暨南大学 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CN105153026B (zh) * 2015-08-21 2018-02-02 江西科技师范大学 含联芳基酰胺结构的索拉非尼衍生物及其制备方法和应用
CN105237523B (zh) * 2015-10-08 2018-06-01 深圳市博圣康生物科技有限公司 嘧啶衍生物及其制备方法、用途
AU2017227516B2 (en) 2016-03-02 2022-03-03 Medivir Aktiebolag Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
AR108107A1 (es) * 2016-04-29 2018-07-18 Syngenta Participations Ag Proceso para preparar compuestos herbicidas
WO2018069278A1 (de) * 2016-10-10 2018-04-19 Basf Se Katalysatormodifikation mit alkalimetall-, erdalkalimetall- oder seltenerdmetallionen in der kontinuierlichen flüssigphasen-hydrierung von nitroverbindungen
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
EP3744718A4 (en) 2018-06-01 2021-11-17 Adlai Nortye Biopharma Co., Ltd. HIGHLY ACTIVE CSF1R INHIBITOR CONNECTION
CN109096250A (zh) * 2018-09-25 2018-12-28 辽宁大学 含哒嗪酮的4-苯氧基吡啶类化合物及其应用
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
KR20220011705A (ko) * 2019-05-24 2022-01-28 메드샤인 디스커버리 아이엔씨. c-MET/AXL 억제제로서의 결정형
JP2023507816A (ja) * 2019-12-20 2023-02-27 エンジン バイオサイエンシズ プライベート リミテッド がんを治療するための方法及び組成物
CN113912628B (zh) * 2020-07-10 2023-05-02 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途
WO2022270881A1 (ko) * 2021-06-22 2022-12-29 주식회사 엘지화학 단백질 키나아제 억제제로서의 신규한 화합물
CN114213404B (zh) * 2021-12-27 2024-08-06 武汉九州钰民医药科技有限公司 Vegfr抑制剂替沃扎尼的合成工艺
CN114796227B (zh) * 2022-05-30 2023-12-01 中山大学 Ponatinib在制备预防或治疗血管退行性疾病药物中的应用及该药物
CN114903996B (zh) * 2022-06-22 2023-10-20 武汉大学中南医院 Hedgehog通路的特异性抑制剂在制备用于治疗宫腔粘连的药物中的应用
KR20240101434A (ko) * 2022-12-23 2024-07-02 주식회사 엘지화학 Ron 억제제로서 신규한 화합물
CN116283920B (zh) * 2023-03-31 2024-04-16 贵州医科大学 2,4-二取代吡啶类化合物及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
EP1352956A1 (en) 1993-11-30 2003-10-15 McGILL UNIVERSITY Inhibition of DNA methyltransferase
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6268137B1 (en) 1996-05-22 2001-07-31 Methylgene, Inc. Specific inhibitors of DNA methyl transferase
JP2002512508A (ja) 1997-05-30 2002-04-23 マクギル・ユニヴァーシティ Ｄｎａメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド
US6020318A (en) 1997-05-30 2000-02-01 Methylgene, Inc. DNA methyltransferase genomic sequences and antisense oligonucleotides
US6066625A (en) 1998-02-03 2000-05-23 Methylgene, Inc. Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
US6953783B1 (en) 1998-10-19 2005-10-11 Methylgene, Inc. Modulation of gene expression by combination therapy
CA2366408A1 (en) 1999-05-03 2000-11-30 Methylgene, Inc. Inhibition of histone deacetylase
WO2001038322A1 (en) 1999-11-23 2001-05-31 Methylgene, Inc. Inhibitors of histone deacetylase
US7288567B2 (en) 2000-03-24 2007-10-30 Methylgene Inc. Inhibitors of histone deacetylase
AU2001298014A1 (en) 2000-03-24 2003-01-29 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
CA2465978C (en) 2001-09-14 2015-04-07 Soon Hyung Woo Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
JP2006503082A (ja) 2002-10-17 2006-01-26 メシルジーン、インコーポレイテッド ヒストンデアセチラーゼの阻害剤
KR101153335B1 (ko) 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
WO2005037273A1 (en) * 2003-10-16 2005-04-28 Chiron Corporation Substituted benzazoles and use thereof as inhibitors of raf kinase
CA2559733C (en) 2004-03-26 2014-05-13 Methylgene Inc. Inhibitors of histone deacetylase
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
JP5096142B2 (ja) 2004-07-30 2012-12-12 メチルジーン インコーポレイテッド Ｖｅｇｆレセプターおよびｈｇｆレセプターシグナル伝達の阻害剤
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2008046216A1 (en) 2006-10-18 2008-04-24 Methylgene, Inc. Kinase inhibitors and uses thereof
PT2089364E (pt) 2006-11-08 2013-08-26 Bristol Myers Squibb Co Compostos de piridinona
JP5314050B2 (ja) 2008-01-23 2013-10-16 ブリストル−マイヤーズ スクイブ カンパニー ４−ピリジノン化合物および癌についてのその使用
WO2009094427A1 (en) 2008-01-23 2009-07-30 Bristol-Myers Squibb Company 4-pyridinone compounds and their use for cancer
CN101952287B (zh) 2008-02-28 2013-11-27 默克专利有限公司 蛋白激酶抑制剂及其应用
US20110104161A1 (en) * 2008-05-14 2011-05-05 Burgess Teresa L Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
AU2009300328A1 (en) * 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
KR20110075016A (ko) * 2008-10-14 2011-07-05 닝 시 화합물 및 사용 방법
KR100961410B1 (ko) * 2008-10-14 2010-06-09 (주)네오팜 단백질 키나제 억제제로서 헤테로사이클릭 화합물
CA2752421C (en) 2009-03-21 2013-08-06 Ning Xi Amino ester derivatives, salts thereof and methods of use
WO2011017142A1 (en) 2009-08-06 2011-02-10 Merck Patent Gmbh Novel bicyclic urea compounds
CN102140093A (zh) 2010-02-03 2011-08-03 上海源力生物技术有限公司 吡啶酮酰胺类衍生物、其制备方法及其在医药上的应用
US8569319B2 (en) 2010-04-29 2013-10-29 Deciphera Pharmaceuticals, LLS Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
WO2012006960A1 (en) 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. NOVEL FUSED HETEROCYCLIC DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
KR20130108318A (ko) 2010-08-27 2013-10-02 메르크 파텐트 게엠베하 푸로피리딘 유도체들
WO2012044577A1 (en) * 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
SG190735A1 (en) 2011-02-28 2013-07-31 Calitor Sciences Llc Substituted quinoline compounds and methods of use
CN102816175B (zh) 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
EP2739143B1 (en) 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
SG11201402531XA (en) 2011-11-22 2014-08-28 Deciphera Pharmaceuticals Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
WO2013180949A1 (en) 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use
US8969388B1 (en) * 2012-07-28 2015-03-03 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use

Also Published As

Publication number Publication date
CA2876246A1 (en) 2014-02-06
JP2015530975A (ja) 2015-10-29
AU2013296897B2 (en) 2015-09-17
BR112015001528A2 (pt) 2017-08-22
US8969388B1 (en) 2015-03-03
US20150050239A1 (en) 2015-02-19
ES2634414T3 (es) 2017-09-27
RU2650895C2 (ru) 2018-04-18
WO2014022116A2 (en) 2014-02-06
CA2876246C (en) 2019-05-07
WO2014022117A1 (en) 2014-02-06
EP2879677B1 (en) 2017-06-14
AU2013296897A1 (en) 2014-12-18
RU2015106605A (ru) 2016-09-20
WO2014022116A3 (en) 2015-07-16
EP2879676A4 (en) 2015-12-09
EP2879676A1 (en) 2015-06-10
JP2015523390A (ja) 2015-08-13
HK1208341A1 (en) 2016-03-04
JP6342393B2 (ja) 2018-06-13
EP2879677A4 (en) 2016-06-01
WO2014022116A8 (en) 2015-04-02
EP2879676B1 (en) 2017-06-14
EP2879677A2 (en) 2015-06-10
BR112015001528B1 (pt) 2020-12-22
JP6342392B2 (ja) 2018-06-13

Similar Documents

Publication Publication Date Title
MX2015001424A (es) Compuestos pirazolona sustituidos y metodos de uso.
MX352844B (es) Compuestos de quinolina sustituidos y metodos de uso.
AU2018236800B2 (en) DNA-PK inhibitors
WO2014193647A3 (en) Alkenyl compounds and methods of use
PH12016501107B1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
MY180641A (en) Heteroaromatic compounds as pi3 kinase modulators and methods of use
MX342509B (es) Compuestos de indazol sustituidos como inhibidores de las cinasas de proteina.
PH12015500963A1 (en) Tricyclic fused thiophene derivatives as jak inhibitors
WO2014019908A3 (en) Substituted pyrroles active as kinases inhibitors
MY182036A (en) Heteroaromatic compounds as pi3 kinase modulators
SG194718A1 (en) Novel compounds as modulators of protein kinases
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
EA201400772A1 (ru) Варианты полипептидов ph20, композиции на их основе и их применение
MY174196A (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
MY169268A (en) Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5-disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
MX366308B (es) Derivados de amida como bloqueadores de ttx-s.
NZ702253A (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MX2015005361A (es) Derivados de pirazolopiridina como bloqueadores de ttx-s.
EA201690655A1 (ru) Новые соединения в качестве модуляторов протеинкиназ
EA202092370A1 (ru) Новые модуляторы киназ